NCT01782170Unknown2 期
Phase II Study: Evaluate Efficacy of Iocide Oral Rinse in a Human Clinical Trial of Gingival Inflammation and Investigate Effects on Biological Markers Indicative of Systemic Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 76
- 试验地点
- 1
- 主要终点
- Change in Mean Gingival Index (GI)
研究概览
简要总结
The purpose of this study is to explore the efficacy of Iocide oral rinse in a human clinical trial of gingivitis. Iocide oral rinse will be evaluated against a placebo rinse. Indices for gingivitis, plaque and bleeding will be scored and blood tests will be performed to determine the effect of the antimicrobial oral rinse on relative levels of biological markers of inflammation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects shall meet all of the following inclusion criteria to be eligible for participation in this study:
- •Males or non-pregnant females of at least 18 years of age, and in good general health, as determined by Investigator;
- •Have at least 16 natural, gradable teeth and good dental health, as determined by Investigator;
- •Have > 25% sites with Gingival Index (GI) scores of > 2 at Visits 1 and 2;
- •Have Plaque Index (PI) scores of > 1 on > 50% of sites;
- •Use of effective method of contraception for the duration of the study or permanently sterilized;
- •Able and willing to comply with study requirements including following instructions on study treatment and returning for follow-up visits as required by the protocol;
- •Have full understanding of all elements of, and signature and dating of the written informed consent prior to the initiation of protocol specified procedures;
- •Females with childbearing potential must have a negative pregnancy test before and during the study period. Sexually active females must be using an effective form of birth control or abstinence. These methods include oral contraceptives ("the pill"), an intrauterine device (IUD), levonogestrol implants (Norplant®), medroxyprogesterone acetate injections (Depo-provera®) or contraceptive foam with a condom.
排除标准
- •Subjects meeting any of the following exclusion criteria will not be eligible for participation in this study:
- •History, or current evidence, of any significant acute or chronic subject-reported medical or psychiatric condition that, in the opinion of the Investigator, would render examination difficult or invalid or prevent the subject from active study participation;
- •≤24% of sites with GI score >2;
- •Thyroid peroxidase antibody (TPOab) positive >34;
- •Screening serum level of thyroid stimulating hormone (TSH) <0.45 or >4.5;
- •Treatment with antibiotic within the one (1) month period prior to the screening examination;
- •History of heart murmur, history of rheumatic fever, valvular disease, prosthetic implant or any other condition requiring antibiotic premedication;
- •History of thyroid disease;
- •Purported sensitivity or allergy to iodine;
- •Known sensitivity or allergy to shellfish;
- •History of diabetes;
- •History of autoimmune disease;
- •Gross oral pathology (periodontal disease, rampant caries, tissue damage created by poor oral care or treatment, soft or hard tissue tumors) that, in the opinion of the Investigator, could influence the outcome of the study;
- •True periodontal pockets of > 5 mm and/or visible recession indicative of attachment loss;
- •Current signs or symptoms of mucosal tissue ulcerations or inflammation, or canker sores;
- •Presence of orthodontic appliances or any removable appliance that impinges on the oral tissues being assessed;
- •History of early onset periodontal disease or acute necrotizing ulcerative gingivitis;
- •Subject reported history in past 6 months or current alcohol abuse that, in the opinion of the Investigator, could influence the outcome of the study;
- •Subject reported history of last past 6 months or current drug abuse;
- •Chronic treatment (2 weeks or more) with any medication known to affect periodontal status (including phenytoin, calcium antagonists, cyclosporine, coumarin, non-steroidal antiinflammatory drugs, and aspirin) within 1 month of the screening examination. All other medications for chronic medical conditions have been initiated at least 3 months before enrollment;
- •Current use of a statin or the use of a statin within the past sixty (60) days of screening;
- •Concomitant therapy with another investigational drug or device without prior approval from the Sponsor within four weeks prior to Visit 2 (Study Day 1);
- •Concomitant endodontic or periodontal therapy other than prophylaxis in the past six (6) months;
- •Females with childbearing potential with a positive pregnancy test, pregnant or nursing mothers, suspected pregnancy, or intention to become pregnant during the study;
- •Residence in the same household as a subject already enrolled in the study (inclusion may create blinding and/or compliance issues);
- •Unable and unwilling to comply with the informed consent process, to meet study requirements including following instructions on study intervention, and to return for follow-up visits as required by the protocol.
研究组 & 干预措施
Iocide Oral Rinse
Active Comparator
Iocide Oral Rinse once daily 30 second rinse for 24 weeks
干预措施: Iocide Oral Rinse (Drug)
Placebo Control
Placebo Comparator
Once daily 30 second rinse for 24 weeks
干预措施: Placebo (Drug)
结局指标
主要结局
Change in Mean Gingival Index (GI)
时间窗: Study Days -21 to -7 through Study Day 168
次要结局
- Change in Biological Marker Data(Study Day 1, Day 28, Day 84 and Day 168)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Dose-Response Study of Iocide Oral RinseGingivitisNCT01103102Biomedical Development Corporation97
进行中（未招募）
2 期
Safety and Efficacy of APG-157 in Head and Neck CancerHead and Neck CancerSquamous Cell Carcinoma of Oral CavitySquamous Cell Carcinoma of the OropharynxNCT05312710Aveta Biomics, Inc.24
已完成
2 期
Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck CancerOral MucositisNCT01400620Izun Pharma Ltd110
已完成
2 期
GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or OxaliplatinColorectal CancerNCT00044343GlaxoSmithKline80
已完成
2 期
Pilot Efficacy Study to Treat GingivitisGingival DiseasesNCT00391547Biomedical Development Corporation14